This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: primary prevention

March 2020 Br J Cardiol 2020;27:31–3 doi:10.5837/bjc.2020.007

Primary prevention aspirin among the elderly: challenges in translating trial evidence to the clinic

J William McEvoy, Michael Keane, Justin Ng

Abstract

Introduction The ASPirin in Reducing Events in the Elderly trial (ASPREE), published in 2018, was a landmark randomised-controlled trial (RCT) that contributed important knowledge about primary cardiovascular disease (CVD) prevention among healthy older adults.1 ASPREE found that daily low-dose aspirin (LDA) does not statistically prevent disability or CVD among adults aged over 70 years when compared with placebo, but does significantly increase risk of haemorrhage; findings that immediately influenced clinical practice guidelines.2 When used as a case study of large RCTs, ASPREE provides further, more existential, lessons for both researche

| Full text
Incidence screening for primary prevention ICDs based on UK guidelines following STEMI

November 2012 Br J Cardiol 2012;19:170–2 doi:10.5837/bjc.2012.030

Incidence screening for primary prevention ICDs based on UK guidelines following STEMI

Ellen Berry, Helen Padgett, Melanie Doyle, Arif J Ahsan, Andrew D Staniforth

Abstract

Introduction The implantable cardioverter defibrillator (ICD) implant rate within the UK remains significantly lower than that across Europe; furthermore, there is marked inequity in access to ICD implant between regions within the UK.1 The need for an ICD is self-evident in secondary prevention patients successfully resuscitated from ventricular tachycardia (VT) or ventricular fibrillation (VF). Intuitively, therefore, it would seem most likely that underperformance and inequity of access in the UK resides chiefly within the primary prevention patient group. A number of international randomised-controlled trials have identified patient subgr

| Full text

March 2012 Br J Cardiol 2012;19:10

Aspirin in primary prevention: new meta-analysis

News from the world of cardiology

Abstract

The authors, led by Professor Kausik Ray (St George’s University of London) conclude that the modest benefits and the significant increase in risk of bleeding do not justify routine use of aspirin in primary prevention, but that aspirin may be considered in certain higher-risk groups. The recently published meta-analysis (Arch Intern Med 2012;172:209–16), included nine randomised placebo-controlled trials with a total of 100,000 participants. Results (table 1) showed that during a mean follow-up of six years, aspirin treatment reduced total cardiovascular events by 10%, driven primarily by a reduction in non-fatal myocardial infarction (M

| Full text

May 2006 Br J Cardiol 2006;13:196-202

Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK

Andrew Davies, John Hutton, John O'donnell, Sarah Kingslake

Abstract

No content available

| Full text

March 2005 Br J Cardiol 2005;12:149-54

Organising primary prevention: an approach by multifactorial risk score profile

John M Waddell, Caron Neal

Abstract

No content available

| Full text

April 2002 Br J Cardiol 2002;9:241-4

Can we do more to get patients to cholesterol targets?

Richard Hobbs

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now